[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Children's Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":279},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,41,67,91,115,140,167,190,212,232,257],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100638770","multimodal-assisted-diagnosis-for-pediatric-respiratory-diseases-using-questionnaires-cough-sounds-and-breath-sounds-100638770",false,"NCT07613242","Multimodal Assisted Diagnosis for Pediatric Respiratory Diseases Using Questionnaires, Cough Sounds, and Breath Sounds","A Prospective Observational Study of Multimodal Assisted Diagnosis for Pediatric Respiratory Diseases Using Symptom Questionnaires, Cough Sounds, and Breath Sounds","Inclusion Criteria:\n\nChildren aged 28 days to 18 years, regardless of sex, will be eligible for inclusion. The disease group will include children presenting to the outpatient department, emergency department, or inpatient wards of Shanghai Children's Medical Center with cough, wheezing, fever with respiratory symptoms, nasal congestion, rhinorrhea, sore throat, or other respiratory complaints. Participants should be able to complete the symptom questionnaire, cough sound recording, and breath sound recording, and their guardians must provide informed consent and allow review of relevant medical history and diagnostic information. The healthy control group will include children recruited from routine health examinations or children without respiratory complaints, with no acute respiratory symptoms within the past 4 weeks, no known history of chronic respiratory diseases, no obvious respiratory abnormalities on health assessment or research team review, the ability to complete relevant data collection, and guardian informed consent.\n\nExclusion Criteria:\n\nParticipants will be excluded if they have severe cardiopulmonary malformations, long-term tracheostomy or mechanical ventilation, severe neuromuscular disorders, severe immunodeficiency, or other conditions that may substantially alter cough sound characteristics or affect the clinical presentation of respiratory diseases. Children whose primary diagnosis at the current visit is a non-respiratory disease and who are not suitable for this study will also be excluded. Participants who are unable to complete the symptom questionnaire, or whose cough sound or breath sound recordings remain of insufficient quality after repeated attempts, will not be included or will be excluded from the corresponding modality-specific analysis. Participants with only one unavailable modality may be included in analyses based on the completed modalities but will be excluded from analyses requiring the missing modality. Healthy controls will be excluded from the main control analysis if recent respiratory symptoms, a history of chronic respiratory disease, or other conditions that may affect acoustic features are identified.",true,"ALL","28 Days","18 Years",{"count":21,"type":22},1400,"ESTIMATED","OBSERVATIONAL","This study aims to establish a standardized, synchronized data collection system for pediatric symptom questionnaires, cough sounds, and breath sounds, and to construct a multimodal database of pediatric respiratory diseases including both disease cases and healthy controls. Using the final research labels determined by clinicians' diagnoses, health status assessments, and research team review as the reference standard, this study will develop and validate a multimodal assisted diagnostic model for common pediatric respiratory diseases based on symptom questionnaires, cough sounds, and breath sounds. The study will primarily evaluate the diagnostic performance of the model in distinguishing healthy children from children with respiratory diseases, screening for asthma and asthma-related cough, and identifying pneumonia, tracheitis\u002Fbronchitis, upper airway-related diseases, and common causes of chronic cough. It will also assess the incremental value of cough sounds and breath sounds beyond symptom questionnaire information.",[26,27],"Asthma (Diagnosis)","Community-Acquired Pneumonia (CAP)","NOT_YET_RECRUITING","2026-05-23",{"date":31,"type":32},"2026-05-29","ACTUAL",{"date":34,"type":22},"2026-06-01",{"date":36,"type":22},"2029-05-31",{"name":38,"class":39},"Shanghai Children's Medical Center","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":19,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":40},"100399216","phase-3-a-multi-institutional-study-for-treatment-of-children-with-newly-diagnosed-hepatoblastoma-using-a-modified-phitt-strategy-100399216","NCT04478292","A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy","A Phase 3 Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy Incorporating a Randomized Assessment of Sodium Thiosulfate as Otoprotection for Children With Localized Disease, and Response Adapted Therapy for Patients With Metastatic Disease","Inclusion Criteria:\n\n* Performance Level Patients must have a performance status corresponding to ECOG scores 0, 1, or 2. Use Karnofsky for patients \\>16 years of age and Lansky for patients ≤16 years of age.\n* Diagnosis Patients must be newly diagnosed with histologically-proven primary pediatric HB\n* Emergent Treatment for HB In emergency situation when a patient meets all other eligibility criteria and has had baseline required observations, but is too ill to undergo a biopsy safely, the patient may be enrolled without a biopsy.\n* Prior Therapy Patients may have had surgical resection of the hepatic malignancy prior to enrollment. All other anti-cancer therapy for the current liver lesion is prohibited.\n* Organ Function Requirements\n\nI) Adequate renal function defined as:\n\nCreatinine clearance or radioisotope Glomerular Filtration Rate (GFR) ≥ 70 mL\u002Fmin\u002F1.73 m2\n\nII) Adequate liver function defined as:\n\nTotal bilirubin ≤ 5 x upper limit of normal (ULN) for age, and Aspartate aminotransferase (AST) or Alanine transaminase (ALT) \\\u003C 10 x upper limit of normal (ULN) for age.\n\nIII) Adequate pulmonary function defined as:\n\nNormal pulmonary function tests (including DLCO) if there is clinical indication for determination (e.g. dyspnea at rest, known requirement for supplemental oxygen)\n\nExclusion Criteria:\n\n* Prior chemotherapy or tumor directed therapy expect for surgical resection of the hepatic malignancy (i.e. radiation therapy, biologic agents, local therapy (embolization, radiofrequency ablation, and laser)). Therefore, patients with a pre-disposition syndrome who have a prior malignancy are not eligible.\n* Patients who are currently receiving another investigational drug.\n* Patients who are currently receiving other anticancer agents.\n* Patients with uncontrolled infection.\n* Patients who previously received a solid organ transplant.",{"count":49,"type":22},330,"INTERVENTIONAL",[52],"PHASE3","A Phase 3 multi-institutional study for treatment of children with newly diagnosed hepatoblastoma using a modified Paediatric Hepatic International Tumour Trial (PHITT) strategy incorporating a randomized assessment of sodium thiosulfate as auditory protection for children with localized disease, and response adapted therapy for patients with metastatic disease",[55],"Hepatoblastoma",[57],"hepatoblastoma, sodium thiosulfate, auditory protection","RECRUITING","2026-04-28",{"date":61,"type":32},"2026-05-04",{"date":63,"type":32},"2021-03-01",{"date":65,"type":22},"2027-09-30",{"name":38,"class":39},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":19,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":40},"100622458","multimodal-tongue-pulse-information-fusion-for-syndrome-diagnosis-and-cohort-study-in-children-with-asthma-100622458","NCT07383883","Multimodal Tongue-Pulse Information Fusion for Syndrome Diagnosis and Cohort Study in Children With Asthma","Inclusion Criteria:\n\n* Children aged 5 to 18 years.\n* Clinically diagnosed asthma according to established pediatric asthma guidelines.\n* Receiving routine outpatient follow-up at Shanghai Children's Medical Center.\n* Able to cooperate with tongue image acquisition and pulse wave data collection.\n* Able to perform pulmonary function testing when clinically indicated.\n* Written informed consent obtained from parents or legal guardians, with assent from the child when appropriate.\n\nExclusion Criteria:\n\n* Presence of other chronic respiratory diseases (e.g., cystic fibrosis, bronchiectasis, primary ciliary dyskinesia).\n* Congenital cardiopulmonary malformations or significant cardiovascular disease.\n* Acute respiratory infection or fever at the time of data collection.\n* Severe systemic diseases or immunodeficiency that may affect study participation.\n* Inability to comply with study procedures or incomplete clinical data.","5 Years",{"count":75,"type":22},1000,"Asthma is one of the most prevalent chronic respiratory diseases in children, and accurate phenotyping and disease monitoring remain challenging in routine clinical practice. This observational cohort study aims to investigate the clinical value of multimodal tongue and pulse information in the syndrome diagnosis and phenotypic characterization of pediatric asthma. Children aged 5-18 years with a confirmed diagnosis of asthma will be enrolled at Shanghai Children's Medical Center and followed in routine outpatient care.\n\nStandardized tongue images and pulse wave data will be collected using validated acquisition devices during visits when lung function testing is performed. Quantitative features extracted from tongue and pulse data will be integrated with clinical information, including asthma stage, lung function parameters, eosinophil counts, allergic sensitization status, and Asthma Control Questionnaire-5 (ACQ-5) scores. The primary objective is to evaluate the associations between tongue-pulse multimodal features and asthma clinical stages and pulmonary function. Secondary objectives include exploring their relationships with airway inflammation and asthma control status.\n\nThis study seeks to establish a non-invasive, objective, and quantifiable approach to asthma phenotyping, providing evidence for integrating traditional diagnostic features with modern clinical data to support precision management of pediatric asthma.",[78],"Asthma",[80,81,82],"asthma","Tongue-Pulse Diagnosis","Multimodal Phenotyping","2026-03-06",{"date":85,"type":32},"2026-03-10",{"date":87,"type":32},"2026-02-01",{"date":89,"type":22},"2028-01-31",{"name":38,"class":39},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":97,"maxAge":19,"enrollmentInfo":98,"targetDuration":4,"studyType":50,"phases":100,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":40},"100620002","clinical-study-on-a-novel-strategy-of-individualized-non-invasive-neuromodulation-for-the-treatment-of-tic-disorders-in-children-100620002","NCT07351955","Clinical Study on a Novel Strategy of Individualized Non-Invasive Neuromodulation for the Treatment of Tic Disorders in Children","Inclusion Criteria:\n\n* 1: Children and adolescents aged 5 to 18 years\n\n  2: Meets DSM-5 diagnostic criteria for Tic Disorders (TDs) with normal EEG findings\n\n  3: No prior treatment received for TDs\n\n  4: Full-scale intelligence quotient (FIQ) ≥70 on the Wechsler Intelligence Scale for Children-Revised (WISC-R)\n\nExclusion Criteria:\n\n* 1: WISC-R Full-Scale Intelligence Quotient (FIQ) \\\u003C70\n\n  2: Presence of metal implants in the body ，Non-right-handedness\n\n  3: Head movement (HM) \\>2mm during fMRI scanning, including both translational movement (TM) and rotational movement (RM)\n\n  4: Any other neurological or psychiatric conditions, including but not limited to autism spectrum disorder (ASD), epilepsy, obsessive-compulsive disorder (OCD), etc\n\n  5: Previous head trauma ，Neurological diseases ，Major systemic illnesses","5 Months",{"count":99,"type":22},60,[101],"NA","This study aims to establish a novel personalized closed-loop NiBS\u002FTMS therapeutic strategy and clinical protocol for children with Tic Disorders (TDs) through a series of scientific investigations. Additionally, it seeks to elucidate the underlying neural circuit mechanisms, enhance the therapeutic efficacy of TMS in pediatric TDs, and achieve precision neuromodulation for children with TDs.",[104],"Tic Disorders",[106],"Transcranial Magnetic Stimulation","2026-01-11",{"date":109,"type":32},"2026-01-20",{"date":111,"type":32},"2025-06-01",{"date":113,"type":22},"2026-05-31",{"name":38,"class":39},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":121,"maxAge":19,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":40},"100616517","wenjuanxing-based-multidimensional-etiologic-screening-and-clinical-validation-of-chronic-cough-in-children-100616517","NCT07306637","Wenjuanxing-Based Multidimensional Etiologic Screening and Clinical Validation of Chronic Cough in Children","Inclusion CInclusion Criteria:\n\n1. Children aged 3 to 18 years, any sex.\n2. Presenting for medical care due to cough lasting ≥2 weeks.\n3. No fever within the past 2 weeks.\n4. Caregiver is willing to complete the Wenjuanxing questionnaire and agree to follow-up.\n\nExclusion Criteria:\n\n1. Presence of congenital airway malformations, chronic lung disease, or severe immunodeficiency.\n2. Recent participation in other interventional clinical research.\n3. Unable to complete follow-up as required.","3 Years",{"count":123,"type":22},400,"Chronic cough is a common and burdensome condition in children, with complex and overlapping etiologies that often lead to delayed diagnosis, misdiagnosis, and inappropriate treatment. This prospective, controlled, observational study aims to develop and clinically validate a Wenjuanxing-based, parent-reported, multidimensional etiologic screening questionnaire for pediatric chronic cough. Children aged 3-18 years presenting with cough lasting ≥2 weeks will be enrolled in a tertiary pediatric respiratory clinic and allocated to either a routine-care group or a questionnaire-assisted group. All caregivers will complete the standardized electronic questionnaire, which generates an automated preliminary etiologic suggestion based on symptom patterns, triggers, and associated features. Diagnostic accuracy, treatment effectiveness, and symptom resolution will be evaluated through structured follow-up at two weeks. The primary outcome is the difference in diagnostic accuracy between physicians using routine assessment alone and those supported by the questionnaire. Secondary outcomes include treatment response and prevention of cough chronicity. This study seeks to provide evidence for a scalable, digital, and standardized screening tool to improve early etiologic identification and clinical decision-making in pediatric chronic cough.",[126],"Chronic Cough (CC)",[128,129,130,131],"Pediatric","chronic cough","Etiologic Screening","Electronic Questionnaire","2025-12-14",{"date":134,"type":32},"2025-12-29",{"date":136,"type":22},"2026-01",{"date":138,"type":22},"2027-12",{"name":38,"class":39},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":19,"enrollmentInfo":147,"targetDuration":4,"studyType":50,"phases":149,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":40},"100595697","phase-3-olanzapine-for-prevention-of-vomiting-in-children-and-adolescents-receiving-highly-emetogenic-chemotherapy-100595697","NCT07035821","Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy","Olanzapine for the Treatment of Breakthrough Chemotherapy-Induced Vomiting in Children: An Open-label, Randomized Phase 3 Trial","Inclusion Criteria:\n\n\\- The major inclusion criteria were children aged 5 to 18 years at the time of study entry with documented cancer; receiving NK-1 inhibitor (aprepitant\u002Ffosaprepitant) and 5HT-3 antagonist (ondansetron) and\u002For dexamethasone as prophylactic antiemetics for CINV due to MEC or HEC; minimum body weight of 10 kg; development of breakthrough vomiting after starting prophylactic antiemetics; Lansky performance scale of above 50 (for patients aged 10 years or less) or Eastern Cooperative Oncology Group performance scale less than 3 and normal electrocardiogram (ECG) before the initiation of the prophylactic antiemetics.\n\nExclusion Criteria:\n\n* Children with history of allergy to olanzapine or metoclopramide; patient with renal failure, congestive heart failure, or any uncontrolled disease except for malignancy; serum creatinine more than upper limit of normal (ULN) for age; serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) four times the ULN for age and serum bilirubin 1.5 times ULN for age; patient with history of central nervous system disease including brain metastasis, seizure disorder, or psychosis; patients on treatment with other antipsychotic agents such as risperidone, quetiapine, clozapine, or phenothiazine.",{"count":148,"type":22},100,[52],"Breakthrough chemotherapy-induced vomiting (CIV) is defined as CIV occurring after adequate antiemetic prophylaxis. Olanzapine is recommended for the treatment of breakthrough CIV in children, without adequate evidence. We conducted an open-label, single-center, phase 3 randomized controlled trial comparing the safety and efficacy of olanzapine and metoclopramide for treating breakthrough CIV.",[152,153],"Breakthrough Chemotherapy-Induced Vomiting (CIV) in Pediatric Patients","Pediatric Cancer",[155,156,157,158],"chemotherapy","olanzapine","pediatric cancer","vomiting","2025-06-16",{"date":161,"type":32},"2025-06-25",{"date":163,"type":22},"2025-07-01",{"date":165,"type":22},"2026-07-30",{"name":38,"class":39},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":50,"phases":176,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":187,"leadSponsor":189,"locationsCount":40},"100593183","a-cohort-study-on-treating-primary-nocturnal-enuresis-by-regulating-central-peripheral-circadian-rhythm-100593183","NCT07003126","A Cohort Study on Treating Primary Nocturnal Enuresis by Regulating Central-Peripheral Circadian Rhythm","Inclusion Criteria:\n\n1. Diagnosis according to the ICCS criteria:\n\n   At least one episode of involuntary nighttime urination per month for more than 3 months.\n\n   No abnormalities in routine urinalysis. No period of bedwetting-free days lasting more than 6 months, except for organic diseases.\n2. Age: 5 to 15 years (inclusive), regardless of gender.\n3. Right-handedness (as assessed by the Annett Hand Preference Questionnaire)\n\nExclusion Criteria:\n\n1. Secondary nocturnal enuresis;\n2. History of head trauma, neurological disorders, psychosurgery, or major physical conditions (including autism spectrum disorder, epilepsy, cerebral palsy);\n3. Contraindications to fMRI.\n4. Note: Mild comorbidities commonly associated with primary nocturnal enuresis (e.g., ADHD) are permitted but must be included as covariates in statistical analyses.","15 Years",{"count":175,"type":22},200,[101],"Primary nocturnal enuresis (PNE), a prevalent pediatric disorder, suffers from therapeutic limitations characterized by low efficacy and high relapse rates. Targeting its core pathophysiology could significantly improve treatment outcomes. Growing evidence implicates circadian dysregulation in PNE pathogenesis. Our preliminary fMRI cohort identified abnormal functional connectivity between the suprachiasmatic nucleus (SCN, the central circadian pacemaker) and superior temporal gyrus in PNE patients, with clinical data confirming circadian realignment correlates with symptom remission. Small-scale pilot studies and clinical observations indicate that modulating central and peripheral circadian rhythms significantly alleviates PNE symptoms. This study will establish a circadian-focused PNE cohort to quantify therapeutic efficacy and elucidate underlying mechanisms, ultimately driving the development of mechanism-based therapies for PNE.",[179],"Primary Nocturnal Enuresis",[179,181,182],"Circadian Rhythm","Treatment","2025-06-03",{"date":185,"type":32},"2025-06-04",{"date":163,"type":22},{"date":188,"type":22},"2028-06-01",{"name":38,"class":39},{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":19,"enrollmentInfo":198,"targetDuration":4,"studyType":50,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":211,"locationsCount":40},"100592993","micturition-desire-relaxation-training-device-for-lower-urinary-tract-dysfunction-in-children-100592993","NCT07000656","Micturition Desire-Relaxation Training Device for Lower Urinary Tract Dysfunction in Children","Prospective Evaluation of Micturition Desire-Relaxation Training Device for Treating Lower Urinary Tract Dysfunction in Children: A Randomized Controlled Pilot Study","ICCS，LUTD，PNE","Inclusion Criteria:\n\n1. Diagnosis according to the ICCS criteria:\n\n   For nocturnal enuresis:\n\n   At least one episode of involuntary nighttime urination per month for more than 3 months.\n\n   No abnormalities in routine urinalysis. No period of bedwetting-free days lasting more than 6 months, except for organic diseases.\n\n   For daytime urinary incontinence:\n\n   At least one episode of intermittent urinary leakage during wakefulness per month for more than 3 months.\n\n   No anatomical or neurological causes of urinary incontinence.\n\n   For urinary frequency:\n\n   The child experiences only urinary frequency and urgency, occurring during the day and before sleep, with intervals ranging from a few minutes to 1 hour. Each urination involves a small volume, less than 50% of the estimated bladder capacity \\[EBC (mL) = 30 + (age × 30)\\], typically less than 30 mL, sometimes just a few drops, while total daily urine volume remains within normal limits. When the child is engaged in play or focused, the intervals between urination are extended, and urinary frequency symptoms disappear after falling asleep.\n2. Age: 5 to 18 years (inclusive), regardless of gender.\n3. Voluntary participation: The child and their guardian must voluntarily participate in the trial and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Exclude enuresis caused by urinary tract infections, pinworms, myelitis, spinal cord injuries, epilepsy, cerebral developmental disorders, diabetes, and other neurological, urinary, or endocrine diseases, as well as transient enuresis due to excessive activity, mental fatigue, or excessive fluid intake before bedtime.\n2. Exclude conditions causing urinary frequency such as neurogenic bladder, urinary tract infections, urethral syndrome, hypercalciuria, or metabolic diseases.\n3. Patients who have participated in or are currently participating in other clinical trials within the past month.\n4. Patients deemed unsuitable for participation in the clinical trial by the investigator.",{"count":175,"type":22},[101],"Urine storage and voiding are fundamental physiological processes. In clinical settings, many cases of lower urinary tract dysfunction (LUTD) are closely associated with abnormal conditioned reflexes formed in the central nervous system during the urine storage or voiding phases. Relaxation, as a core physiological and psychological state, has been shown to promote effective urine storage and facilitate smooth voiding. By repeatedly training individuals to establish a new conditioned reflex linking the sensation of urinary urgency with a state of relaxation, it may be possible to improve bladder storage capacity and voiding function. Based on this concept, the investigators have developed the world's first Micturition Desire-Relaxation Training Device (Chinese Patent No.: ZL 2020 1 0397789.4). This study aims to evaluate the clinical efficacy of this device in treating LUTD in children.",[202,203,204,179],"Daytime Urinary Incontinence","Urinary Frequency","Lower Urinary Tract Dysfunction","2025-06-02",{"date":207,"type":32},"2025-06-05",{"date":209,"type":32},"2024-11-20",{"date":113,"type":22},{"name":38,"class":39},{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":19,"enrollmentInfo":218,"targetDuration":4,"studyType":50,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":40},"100549965","study-on-theraputic-drug-monitoring-and-phamacokinetics-of-isavuconazole-in-children-100549965","NCT06440915","Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children","Inclusion Criteria:\n\n* Patients who intend to take isavuconazole for the treatment of invasive mycosis;\n* Aged 0-18 years, gender unlimited;\n* The subject and his\u002Fher guardian are willing to comply with the procedures and operations specified in the study protocol;\n* The guardian of the subject and the subject of independent informed age are willing and able to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* The subject is known to be allergic to any azole antifungal therapy or other ingredients contained in the study drug;\n* The researcher believes that the condition of the child may interfere with study participation or other inappropriate conditions.",{"count":175,"type":22},[101],"The goal of this clinical trial is to learn the plasma concentration of isavuconazole in pediatric patients. It will also learn about the relationship of isavuconazole plasma concentrations to efficacy and safety in pediatric patients. The main questions it aims to answer are:\n\nWhat is the plasma concentration after using isavuconazole in pediatric patients? What is the effective range of plasma concentration of isavuconazole in pediatric patients? What is the safe range of plasma concentration of isavuconazole in pediatric patients? Researchers will measure the plasma concentration of isavuconazole to see whether it is appropriate.\n\nParticipants will:\n\nTake drug isavuconazole as prescribed by the doctor;\n\n1mL of blood is drawn 30min before the next dose.",[222,223],"Aspergillosis Invasive","Mucormycosis","2024-12-09",{"date":226,"type":32},"2024-12-13",{"date":228,"type":32},"2024-06-06",{"date":230,"type":22},"2026-06-30",{"name":38,"class":39},{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":17,"minAge":239,"maxAge":19,"enrollmentInfo":240,"targetDuration":4,"studyType":50,"phases":241,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":256,"locationsCount":40},"100421866","phase-3-a-prospective-study-for-the-treatment-of-children-with-newly-diagnosed-lch-using-a-cytarabine-contained-protocol-100421866","NCT04773366","A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol","A Prospective Institutional Study for the Treatment of Children With Newly Diagnosed Langerhans Cell Histiocytosis Using a Cytarabine Contained Protocol","Inclusion Criteria:\n\n1. Age under 18 years\n2. Newly diagnosed LCH：Morphologic identification of the characteristic LCH cells, positive staining of the lesional cells with CD1α and\u002For Langerin\n3. No congenital immunodeficiency, HIV infection, or prior organ transplant\n4. No previous chemotherapy\u002Ftarget therapy\u002Fradiation, if any steroid applied, total prior steroids dosage \\\u003C prednisone 280 mg\u002Fm2\n\nExclusion Criteria:\n\n* Patients have overwhelming infection, and a life expectancy of \\\u003C 2 weeks","1 Day",{"count":175,"type":22},[52],"From January 2010 to December 2014, 150 children with MS-LCH were treated in our hospital following a LCH II (Arm B) based protocol. Treatment was based on a modification of the LCH-II (Arm B) based protocol. However, the continuation treatment was extended to 56 weeks and etoposide was omitted from the continuation treatment.\n\nFor the 59 patients with RO involvement (RO+) (the lungs are not considered a RO in the current study), the rapid response rate (week 6) was 61.0% and the 3-year overall survival (OS) 73.4±5.9%. Rapid responders had a better 3-year survival rate than poor responders (90.9±5.0% vs. 45.7±11.0%, P\\\u003C0.001). The 3-year OS in the current study is 10\\~20% lower than the rates reported by Gadner et al. and Morimoto et al.. We have not yet adopted effective salvage therapies for RO+ patients with recurrent disease. During the time of this study, cladribine was unavailable. Second-line therapy for non-responders or patients with disease reactivation was individualized treatment based on the physician's experience. An effective salvage therapy is essential for this high-risk group.\n\nFor 91without RO involvement (RO-), 78 patients (85.7%) were rapid responders at week 6. The 3-year cumulative reactivation rate was 10.7% for RO- patients. No death occurred in this subgroup, with a 3-year OS of 100% in RO- patients. Compared to the LCH II and LCH III trials, the current study had a more intensive initial treatment regimen for RO- patients. However, the addition of etoposide to prednisone and vincristine in the initial therapy did not increase the 6-week response rate for RO- patients (85.7% in this study compared to 83% in the LCH II study and 86% in the LCH III study). Surprisingly, with a relatively intense initial treatment, a relatively low 3-year cumulative reactivation rate was observed in RO- patients in the current study. This result suggests that the initial treatment intensity and duration of continuation therapy both impact disease reactivation. The intensity of induction can affect the degree of disease resolution. Insufficient treatment intensity might lead to late relapse. Similarity to that observed has been in other childhood hematological malignancies. This finding deserves to be tested in prospective clinical trials with long-term follow-up. Cytarabine has been applied for patients with LCH but has never been evaluated in our hospital prospectively. In this study, we administer a cytarabine contained protocol to patients with multisystem involvement with or without risk organs involvement. The treatment results will be compared with our historical studies.",[244],"Langerhans Cell Histiocytosis",[246,247,248,249],"Langerhans cell histiocytosis","pediatric patients","cytarabine","treatment outcome","2022-07-23",{"date":252,"type":32},"2022-07-26",{"date":254,"type":32},"2018-07-01",{"date":230,"type":22},{"name":38,"class":39},{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":17,"minAge":264,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":40},"100440599","long-term-health-cohort-of-premature-infants-100440599","NCT05017389","Long Term Health Cohort of Premature Infants","A Cohort Study on the Long-term Health Outcomes of Premature Infants","Inclusion Criteria:\n\n1. Live born newborns with gestational age ≤ 36 + 6 weeks\n2. Transfer to the neonatal ward of Shanghai Children's medical center within 24 hours after birth\n3. Those who have lived in Shanghai for more than 1 year and plan to live in Shanghai for a long time. Parents voluntarily participated in the study and signed informed consent\n\nExclusion Criteria:\n\n1. Premature infants: termination of treatment due to family factors (non-disease reasons) and hospitalization time ≤ 2 weeks\n2. Major congenital malformations\n3. Parents refuse to participate in the study","15 Days","4 Months",{"count":267,"type":22},1200,"Establish a clinical diagnosis and treatment and long-term follow-up database of preterm infants, and analyze the effects of prenatal factors (including genetic characteristics, maternal diseases, etc.), postnatal diagnosis and treatment measures and family maintenance environment after discharge on preterm infant mortality and major diseases in the near and long term.",[270],"Preterm","2021-08-17",{"date":273,"type":32},"2021-08-23",{"date":275,"type":32},"2021-01-01",{"date":277,"type":22},"2041-12-31",{"name":38,"class":39},""]